Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HTMC0435
- Development stage
- Phase 2
- Lead developer
- Shanghai Yidian Pharmaceutical Technology Development
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HTMC0435 is an investigational small molecule drug that acts as a poly (ADP-ribose) polymerase (PARP) inhibitor, specifically targeting PARP1 and PARP2. It is being developed for the treatment of various advanced solid tumors, with a primary focus on recurrent extensive stage small cell lung cancer (SCLC). The drug is administered orally and has reached Phase 2 clinical trials in China for indications including biliary tract cancer, neuroendocrine tumor of the pancreas, advanced malignant solid neoplasms, and SCLC. Its mechanism involves inhibiting DNA repair in cancer cells by blocking PARP enzymes, thereby promoting cell death in tumor cells reliant on these pathways for survival. The developers are Shanghai Huilun Life Science and Technology Co., Ltd. and Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.[1][2][3][7]
- Other names
- HTMC0435HTMC-0435HTMC 0435
02
Targets
PARP1 (Poly (adp-ribose) polymerase 1)PARP2 (Poly (adp-ribose) polymerase 2)Pol II (RNA polymerase II elongation factors)
Beyond the preview
Go deeper on HTMC0435.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HTMC0435.